ArticleBMJ open2025
Prognostic value of C-reactive protein predicting all-cause and cause-specific mortality: a prospective cohort study in Shanghai, China.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- High Prevalence of Vitamin D Deficiency in Critically Ill Patients in Tropical Southern Taiwan: Risk Factors and Clinical Outcomes.Journal of clinical medicine · 2026Article
- Observational
- The Confounder in Plain Sight: A Retrospective Pilot Analysis on the Impact of Comorbidity on C-Reactive Protein Utility for Differentiating Bacterial vs. Viral Infections.Antibiotics (Basel, Switzerland) · 2026Article
- ABO Blood Group and Biomarker-Based Risk in Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the role of C-reactive protein (CRP) in predicting all-cause and cause-specific mortality in a community-based Chinese cohort.
designA community-based prospective cohort study.
setting34 communities in Pudong New Area, Shanghai, China.
participantsA total of 9360 permanent residents from 34 randomly selected communities were enrolled in 2013. Follow-up began at baseline and continued until death or 30 September 2023, whichever occurred first.
main outcome measuresThe primary outcome of this study was death, as recorded in the Vital Registry of Pudong New Area, Shanghai, China. Associations between CRP and risks of all-cause and cause-specific mortality were studied. Cox proportional hazards models were applied to estimate HR and 95% CI. Adjustments were made for age, sex, area, marriage status, education, current smoking, alcohol consumption, physical activity, body mass index, systolic blood pressure, diastolic blood pressure, type 2 diabetes, dyslipidaemia and chronic kidney disease. Competing risk analyses were performed for cause-specific mortality. Restricted cubic splines were used to assess potential non-linear associations. We evaluated improvements in mortality prediction by calculating changes in the C-index, integrated discrimination improvement and net reclassification improvement after adding CRP to conventional risk factor models.
resultsOver a median follow-up of 10.52 (IQR: 10.43-10.56) years, 920 deaths (9.68 per 1000 person-years) were recorded. After adjusting for traditional risk factors, higher baseline CRP levels were significantly associated with increased risk of all-cause mortality, cardiovascular mortality and cancer mortality. Non-linear associations were observed between CRP levels and all-cause and cancer mortality. The addition of CRP level significantly improved the reclassification and discrimination ability beyond the conventional risk factor models for all-cause mortality and cancer mortality.
conclusionsElevated CRP levels, indicative of low-grade inflammation, are an independent risk factor for all-cause, cardiovascular and cancer mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.